Skip to main content
. 2022 Feb 18;2(3):100110. doi: 10.1016/j.xjidi.2022.100110

Figure 2.

Figure 2

Overview of the QSP model that describes the interactions between Staphylococcus aureus and CoNS in AD pathogenesis. (a) Schematic diagram. (b) Regulatory pathways of the QSP model. The model comprises the EASI score (an efficacy endpoint), skin barrier integrity, agr expression, S. aureus, CoNS, IL-4/IL-13, and treatments (ShA9, flucloxacillin, and dupilumab). The regulatory pathways between biological factors are described according to published human data (“Model structure” in Supplementary Materials and Methods). AD, atopic dermatitis; agr, accessory gene regulatory; AMP, antimicrobial peptide; CoNS, coagulase-negative Staphylococcus; EASI, Eczema Area and Severity Index; QSP, quantitative systems pharmacology; ShA9, Staphyloccocus hominis A9.